Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Trial details
- Registry ID
- NCT04329949
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as CORT125134
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT04329949 | Corcept Therapeutics | Phase 3 | Terminated | 2021-08-23Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |